Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor

Hyo-Sin Kim, Sung-Soo Kim, Sang-Gon Park

Departments of Surgery and Internal Medicine, Chosun University Hospital, Gwangju, Korea

INTRODUCTION

Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract. Most of these tumors (60%–70%) present in the stomach. The treatment of choice is surgical excision of the tumor and resection of infiltrated tissue. Prior to the year 2000, there was no known effective therapy for unresectable or metastatic GIST, because these tumors are extremely resistant to conventional cytotoxic chemotherapy and radiotherapy [1]. The discovery that these tumors express the CD117 antigen has led to substantial advances in the understanding of their biology. We know that GISTs usually have activating mutations in either KIT (75%–80%) or the platelet-derived growth factor receptor-α gene (PDGFR) (5%–10%), which encode 2 closely related receptor tyrosine kinases; therefore, these mutations provide a rationale for the use of targeted therapies [2-4]. Because imatinib mesylate (Gleevec, Novartis Pharma. Basel, Switzerland), an inhibitor of KIT and PDGFR tyrosine kinases, is now available for the treatment of metastatic and unresectable GISTs, it is important to understand the natural history of these tumors [1,2]. Although imatinib has greatly improved the survival of patients with advanced GIST, primary refractoriness or secondary resistance to imatinib therapy occurs in the majority of patients [1,2].

Currently, the only approved second-line drug is sunitinib malate, which was approved in 2006 by the U.S. Food and Drug Administration for the treatment of GIST patients following progression or resistance to imatinib [4]. Sunitinib malate (Sutent, Pfizer. New York, NY, USA) is an oral multitargeted tyrosine kinase inhibitor of KIT, platelet-derived growth factor receptor (PDGFR), all 3 isoforms of vascular endothelial growth factor receptor-α, and vascular endothelial growth factor receptor-β (VEGFR-1, 2, 3), which is a receptor for vascular endothelial growth factor (VEGF) [5,6]. These targets are responsible for angiogenesis, and sunitinib has been shown to have good activity against both GIST and other solid tumors [7,8]. Sunitinib is generally well tolerated and has an acceptable toxicity profile; an adverse event such as bowel perforation is rare. We present a patient with imatinib-refractory GIST who was successfully treated using sunitinib, but developed bowel perforation. The mechanism involved in bowel perforation associated with sunitinib is unknown. However, we presume that in our patient, the dramatic reduction in disseminated peritoneal metastases and bowel invasion of recurrent GIST during sunitinib treatment might have resulted in the bowel perforation.

Key Words: Gastrointestinal stromal tumors, Sunitinib, Intestinal perforation
factor receptor (VEGFR1, VEGFR-2, VEGFR-3). Fms-like tyrosine kinase-3 receptor, and the receptor encoded by the ret protooncogene (RET). The mechanism of sunitinib activity against GIST is similar to imatinib [3,4]. Moreover, sunitinib exerts an additional antiangiogenic activity because it inhibits the activation of VEGFR. Because of this activity, sunitinib has been thought to be beneficial for patients with imatinib-resistant GIST [3,5].

The most common treatment-related adverse events of sunitinib have been reported to be fatigue, diarrhea, skin discoloration, nausea, mucositis, arterial hypertension, hand-and-foot syndrome, decreased left ventricular ejection fraction, and hypothyroidism. However, sunitinib is generally well tolerated and has an acceptable toxicity profile [3,4]. The overall rate of gastrointestinal perforation associated with sunitinib is unknown, since only a few cases have been reported from trials and case reports, and the mechanism of bowel perforation from sunitinib is unknown [5,6].

Here, we present an extremely rare case of bowel perforation associated with sunitinib therapy for GIST.

CASE REPORT

A 78-year-old woman with an abdominal mass for more than 1 month was admitted to Chosun University Hospital. Physical examination revealed a large mass in the periumbilical area. Abdominal computed tomography revealed an 18 cm abdominal mass with extensive central necrosis. She underwent complete resection of the mass, with total gastrectomy, distal pancreatectomy, splenectomy, and transverse colectomy (Fig. 1). Postoperative histopathologic examination showed a gastric GIST with negative resection margins and no metastatic lymph nodes. The mass was a 15 cm × 9 cm gastric GIST with 14 mitoses/50 high-power fields, and was categorized as a high-risk tumor. Immunostaining showed that the tumor was positive for C-KIT and CD34, and negative for S100 expression (Fig. 2). Adjuvant chemotherapy using oral imatinib mesilate was recommended to the patient. However, she declined treatment because it was too expensive.

Eight months after the operation, the patient was found to have recurrent GIST involving the hilum and subcapsular region of the right lobe of the liver and peritoneal nodules. Imatinib (400 mg/day) was started as palliative treatment (Fig. 3A, B). At a 3-month follow-up, the liver masses had decreased and imatinib was found to be well tolerated by the patient, who continued on the same dose of imatinib (Fig. 3C, D). Follow-up imaging 6 months later showed peritoneal seeding in the region of the distal pancreas and a small amount of left pleural effusion and ascites (Fig. 3E, F). The patient refused second-line treatment, and imatinib therapy was continued despite the progression. Two months later, she was admitted because of severe dyspnea due to a large amount of pleural effusion and ascites (Fig. 4A).
She requested second-line palliative oral medication without undergoing additional diagnostic evaluation.

Before she received sunitinib, a complete blood count (CBC) showed the following: white blood cell (WBC) count, 2,990 $\times 10^3/\mu L$; neutrophils, 65% (1,943 $\times 10^3/\mu L$); hemoglobin, 9.1 g/dL; and platelets, 222 $\times 10^3/\mu L$. Partial thromboplastin time (PTT) and activated partial thromboplastin time (aPTT) were in the normal range. The patient's grade I anemia and neutropenia were due to imatinib toxicity. Examination of the pleural effusion revealed the following: WBC, 1,296/m3 (polymorphonuclear cells, 60%); pH, 7.20; lactate dehydrogenase (LDH), 1,266 U/L; and atypical cells. Cultures of the pleural effusate were negative. The results of these laboratory tests suggested malignant pleural effusion.

The patient's therapy was changed to oral sunitinib administered at 50 mg/day in cycles consisting of 4 weeks of sunitinib followed by 2 weeks of rest. On day 7 of the first cycle of sunitinib therapy, the volume of the patient’s pleural effusion was unchanged, but her dyspnea had improved, and she requested discharge from the hospital. On day 21, sunitinib was found to be well tolerated except for grade I neutropenia (WBC, 2,390 $\times 10^3/\mu L$; neutrophils, 1,769 $\times 10^3/\mu L$) with markedly decreased pleural effusion and ascites (Fig. 4B). Oral sunitinib was continued at 50 mg/day.

On day 26 of the first cycle of sunitinib therapy, the patient had a sudden onset of sharp, generalized abdominal pain. An imaging study revealed intraperitoneal free gas with many bubbles near the distal pancreatic region, suggesting small bowel perforation (Fig. 5), and the patient was hospitalized. The admission CBC showed the following: WBC, 1.19 $\times 10^3/\mu L$; neutrophils, 63%; hemoglobin, 10.6 g/dL; and platelet count, 89 $\times 10^3/\mu L$. The PT and aPTT were 10.9 and 25.6 seconds, respectively. She was diagnosed with generalized peritonitis due to bowel perforation and grade III neutropenia (750 $\times 10^3/\mu L$) due to sunitinib toxicity. We recommended emergency surgery; however, the patient's guardian refused consent. The
patient expired the next day.

**DISCUSSION**

Bowel perforation due to the toxicity of chemotherapeutic agents is a serious adverse event, and perforation is known to occur in patients with a chemosensitive malignancy such as gastrointestinal lymphoma [7]. Knowledge of the numerous intracellular signaling pathways involved in tumorigenesis enabled the identification of several potential molecular targets for the therapy of solid tumors. However, adverse events of new targeted therapies, such as bowel perforation and tumor rupture, are new challenges for the surgical oncologist [5]. The overall rate of gastrointestinal perforation associated with sunitinib is unknown [5,6]. One study found that emergency surgery for hemorrhage, tumor perforation, or abscess was needed in 3%–9% of patients receiving second-line therapy with sunitinib [5]. However, gastrointestinal (GI) perforation

**Fig. 3.** (A, B) The gastrointestinal stromal tumor relapsed on the liver hilum and subcapsular area of the right lobe of the liver with peritoneal nodules. (C, D) Three months later of imatinib treatment, the mass of the liver hilum and liver capsule was decreased. (E, F) Follow-up image showed the recurrence of a peritoneal seeding mass in distal pancreatic area and a small amount of left pleural effusion and ascites.

**Fig. 4.** (A) A large amount of pleural effusion showed in left pleural space. (B) On 21 days of sunitinib, chest x-ray revealed markedly decreased pleural effusion.
has been reported in <1% of patients taking sunitinib, and there was an extremely rare case of bowel perforation during sunitinib treatment for GIST [4,8].

The mechanism of bowel perforation associated with sunitinib toxicity is also unknown. Sunitinib has an additional antiangiogenic activity because it inhibits the activation of VEGFR such as bevacizumab. Bevacizumab, the first angiogenesis inhibitor approved for use in the United States, is a humanized anti-VEGF monoclonal antibody well known to be associated with the adverse event of GI perforation. The mechanism causing bowel perforation has also not been established; however, several mechanisms of action have been postulated [9].

Hypothetical mechanisms for GI perforation in patients treated with chemotherapy (including new targeted therapies) include the following: First, these drugs, such as bevacizumab, sunitinib, and sorafenib, block the VEGF receptors on endothelial cells and have a significant impact on the capillary beds of small intestinal villi. Such inhibition was found to significantly reduce the capillary density within these intestinal villi. Hence, antiangiogenic drugs may contribute to the development of microperforations within the intestinal wall secondary to the reduced regenerative capacity of the intestinal mucosa because of decreased blood vessel density. Second, in a variety of localized pathologic conditions, such as tumor-associated peptic ulcer disease, diverticulitis, or colitis, the intraluminal pressure is increased by tumor obstruction. These proposed risk factors may predispose bowel perforation in patients treated with chemotherapy (especially, antiangiogenic therapy). Third, bowel ischemia may be due to various thromboembolic events after antiangiogenic therapy. And last, rapid tumor necrosis as a result of chemotherapy or new targeted therapies may lead to bowel perforation in patients with bowel metastasis or invasion [5-10].

A mechanism for the perforation occurring in our patient during administration of sunitinib as a second-line therapy might have been the rapid death of tumor invading the GI mucosa. The cytotoxic and antiangiogenic activity of sunitinib may have resulted in a dramatic tumor response [3,4,6,8,10].

In conclusion, we presented an extremely rare case of bowel perforation associated with sunitinib therapy for imatinib-refractory GIST. Although we could not obtain pathologic confirmation through emergency surgery, we postulate that the dramatic reduction during sunitinib treatment for disseminated peritoneal metastases and bowel invasion in our patient with recurrent GIST of gastric origin, led to bowel perforation.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.
REFERENCES

1. Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731-41.
2. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
3. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38.
4. Rock EP, Goodman V, Jiang JX, Mahjoob K, Verbois SL, Morse D, et al. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007;12:107-13.
5. Rutkowski P, Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol 2009;10:157-63.
6. Coriat R, Ropert S, Mir O, Billemont B, Chaussade S, Massault PP, et al. Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 2011;29:1090-3.
7. Kim HG, Jung MR, Kang H, Cheong O, Ju JK, Park YK, et al. Discrepant bowel perforation from a primary lesion after chemotheraphy of diffuse large B cell lymphoma. J Korean Surg Soc 2009;76:61-5.
8. Hur H, Park AR, Jee SB, Jung SE, Kim W, Jeon HM. Perforation of the colon by invading recurrent gastrointestinal stromal tumors during sunitinib treatment. World J Gastroenterol 2008;14:6096-9.
9. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-95.
10. Ruka W, Rutkowski P, Szawlowski A, Nowecki Z, Debiec-Rychter M, Grzesiakowska U, et al. Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. Eur J Surg Oncol 2009;35:87-91.